home genetic news bioinformatics biotechnology literature journals ethics positions events sitemap

UBBFriend: Email This Page to Someone!
  Biotechnical requests and sources
  Development gateway for the upgrade of β-lactam antibiotics

Post New Topic  Post A Reply
profile | register | preferences | faq | search

next newest topic | next oldest topic
Author Topic:   Development gateway for the upgrade of β-lactam antibiotics
posted 10-02-2003 04:36 PM     Click Here to See the Profile for elisatireau   Click Here to Email elisatireau     Edit/Delete Message Reply w/Quote
Resistance to antibiotics: health concern

The growing resistance of bacteria against existing antibiotics is urging life scientists to discover new remedies against infectious diseases. Protein’eXpert (PX) is therefore conducting its in-house research on key bacterial molecules, namely Class B Penicillin Binding Proteins (PBPs), as a promising research pathway towards an upgrading of β-lactam antibiotics.
PX’s rational approach combines the identification and structural analysis of targets, with their enzymatic characterisation, high-throughput screening and molecular modelling. PX uses its technological platform and know-how to produce, optimise, crystallise and elucidate the 3D-structure of class B PBPs which are key bacterial molecules because of their close inter-relationship with β-lactams. Cracking the high-resolution 3D-structure of these particular proteins will enable the determination of the optimal β-lactam derivative inhibiting their activity.

State of the Art

PX has taken up the challenge and engineered a so-called “mini-protein” named Mini-PBP2x. This research program is partly developed thanks to proprietary Protein Polishing technology which enables the deletion of a protein’s non-essential floppy loops. The end result is an extremely compact compound. This particular protein possesses a higher structural resolution which yields superior downstream results for drug designers.

The R&D project is founded on the use of Grenoble-based IBS’s (Institute of Structural Biology – part of CEA) patent application entitled : “PBP2x mini-protein of Streptococcus Pneumoniae and applications”.

PX has set up a portfolio of Mini-PBP2x compounds coming from antibiotic-resistant bacteria: wild type & 3 clinical-resistant molecules. PX’s protein engineering technologies have permitted to increase the resolution of the protein’s structure by more than 1 Å to about 1.7 Å. Such a high-resolution enables a precise analysis of ‘protein-antibiotics’ interactions.
In addition, the company is in a position to grant access to a library of clinical-resistant strains for over 2OO candidates of class B PBP2x.

Business Development Opportunities

PX is seeking industrial and financial partners to bring this high-potential research project further along its pipeline. Please contact us for further information or to start exploring partnering options.

About Protein’eXpert, Grenoble, France

PX s.a. is a rapidly expanding biotechnology company working at the crossroads of proteomics, genomics and high-throughput recombinant proteins production. The company’s core mission is to provide premium services to pharmaceutical and biotechnology companies as well as academic laboratories. It strives to accompany them as a key partner within their target or therapeutic protein research programs. PX was founded in 2000 as a spin-off of Grenoble’s IBS with headquarters in the heart of the local scientific community. Leading research facilities like the ESRF (European Synchrotron Research Facility) are located in its vicinity.


Elisa TIREAU, Business Development
Phone : +33 (0) 438 782 180
Fax : +33 (0) 438 782 439
E-mail: ElisaTireau@proteinexpert.com
Address : Protein’eXpert - 15 rue des Martyrs – 38027 Grenoble cedex 1 - France


All times are ET (US)

next newest topic | next oldest topic

Administrative Options: Close Topic | Archive/Move | Delete Topic
Post New Topic  Post A Reply
Hop to:

Contact Us | HUM-MOLGEN

Copyright by HUM-MOLGEN 1995-2017

Powered by: Ultimate Bulletin Board, Version 5.44a
© Infopop Corporation (formerly Madrona Park, Inc.), 1998 - 2000.